Sun Pharmaceutical Industries Limited

₹1,860As of Sun 8 Nov 2026, 12:00 UTC
NSE:SUNPHARMAHealthcare
Country India
PE (Fwd) •••
TSR 10Y CAGR 10.46%
Div yield 0.86%
ROE 13.10%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.13
PE TTM 40.70
TSR TTM 11.02%
Mkt cap ₹4.463T
ROIC 18.40%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹2,252
21.07%
42.92%
Hold 9|3|4|2|5
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
21.85
23.16
25.09
24.31
(0.74%)
4.48%
14.28%
6.02%
Revenue₹B
546.8
531.5
534.9
546.0
1.87%
0.07%
0.83%
1.26%
Peers (US$47.52B)
Cap (US$)
PE
29.17B
81.44x
13.46B
94.44x
49.72B
99.82x
Capital
TTM
5Y
10Y
Leveragex
7.353
(0.027)
(0.027)
EBIT/Intx
9.559
0.691
0.526
Own earn%
(17.55)
(10.79)
4.15
Sh yield%
32.30
51.31
48.59
Owners
Insiders/Inst%
5.59
36.00
Short interest%
2.70
SBC / revenue%
2.56
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
24–31
$1 testx
—
Incr. ROIC%
12

Sun Pharmaceutical Industries Limited is a generic pharmaceutical company that develops, manufactures and markets branded and generic formulations and active pharmaceutical ingredients in India, the United States and internationally, spanning areas such as cardiology, diabetes, oncology and dermatology, plus generic, specialty, antiretroviral and over-the-counter products, and generics and APIs for anti-cancers and peptides.